China GDP grows 5% in Q1, beats expectations on exports, spending strength
William Lewis, Chair and CEO of Insmed Inc (NASDAQ:INSM), sold 10,700 shares of common stock on April 6, 2026, for a total of $1,746,335. The sales occurred at prices ranging from $161.73 to $164.01. The transaction comes as the stock trades at $160.18, near its 52-week high of $212.75, following a remarkable 151% gain over the past year.
On the same day, Lewis also exercised options to acquire 10,699 shares of Insmed common stock. These transactions involved the exercise of stock options at prices of $30.46 and $17.16, totaling $266,839.
Following these transactions, Lewis directly owns 301,185 shares of Insmed Inc. common stock. Additionally, 233,924 shares are held indirectly by the Katie Procter Dynasty Trust.According to InvestingPro analysis, the biopharmaceutical company appears overvalued at current levels relative to its Fair Value. While InvestingPro Tips highlight the stock’s strong momentum, analysts don’t anticipate profitability this year. Investors can access 10 additional ProTips and comprehensive analysis through the platform’s detailed Pro Research Report.
In other recent news, Insmed Incorporated announced the discontinuation of its hidradenitis suppurativa program after the Phase 2b CEDAR study failed to meet its primary or secondary efficacy endpoints. The trial evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa. Following this announcement, H.C. Wainwright lowered its price target for Insmed to $220, while maintaining a Buy rating. Stifel also maintained a Buy rating with a $208 price target, noting that the negative results were expected due to the lack of validation in the disease setting. Mizuho adjusted its price target to $202 from $206, citing the removal of the indication from its financial model. Truist Securities reiterated its Buy rating with a $205 price target after the trial’s failure. These developments reflect the company’s recent challenges in advancing its treatment for this chronic skin condition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.